These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 30930073)

  • 1. Minimizing Hyperglycemia-Induced Vascular Endothelial Dysfunction by Inhibiting Endothelial Sodium-Glucose Cotransporter 2 and Attenuating Oxidative Stress: Implications for Treating Individuals With Type 2 Diabetes.
    Pulakazhi Venu VK; El-Daly M; Saifeddine M; Hirota SA; Ding H; Triggle CR; Hollenberg MD
    Can J Diabetes; 2019 Oct; 43(7):510-514. PubMed ID: 30930073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress.
    El-Daly M; Pulakazhi Venu VK; Saifeddine M; Mihara K; Kang S; Fedak PWM; Alston LA; Hirota SA; Ding H; Triggle CR; Hollenberg MD
    Vascul Pharmacol; 2018 Oct; 109():56-71. PubMed ID: 29908295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose cotransporter inhibitors and oxidative stress: An update.
    Yaribeygi H; Atkin SL; Butler AE; Sahebkar A
    J Cell Physiol; 2019 Apr; 234(4):3231-3237. PubMed ID: 30443936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn
    Olgar Y; Turan B
    Can J Physiol Pharmacol; 2019 Jun; 97(6):528-535. PubMed ID: 30444646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrovascular Complications of Diabetes: SGLT-2 Inhibitors as a Promising Future Therapeutics.
    Chavda V; Vashi R; Patel S
    Curr Drug Targets; 2021; 22(14):1629-1636. PubMed ID: 33081674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor 21 Ameliorates diabetes-induced endothelial dysfunction in mouse aorta via activation of the CaMKK2/AMPKα signaling pathway.
    Ying L; Li N; He Z; Zeng X; Nan Y; Chen J; Miao P; Ying Y; Lin W; Zhao X; Lu L; Chen M; Cen W; Guo T; Li X; Huang Z; Wang Y
    Cell Death Dis; 2019 Sep; 10(9):665. PubMed ID: 31511499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
    Oelze M; Kröller-Schön S; Welschof P; Jansen T; Hausding M; Mikhed Y; Stamm P; Mader M; Zinßius E; Agdauletova S; Gottschlich A; Steven S; Schulz E; Bottari SP; Mayoux E; Münzel T; Daiber A
    PLoS One; 2014; 9(11):e112394. PubMed ID: 25402275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin Prevents Hyperglycemia-Associated, Oxidative Stress-Induced Vascular Endothelial Dysfunction: Essential Role for the Orphan Nuclear Receptor Human Nuclear Receptor 4A1 (Nur77).
    Venu VKP; Saifeddine M; Mihara K; Faiza M; Gorobets E; Flewelling AJ; Derksen DJ; Hirota SA; Marei I; Al-Majid D; Motahhary M; Ding H; Triggle CR; Hollenberg MD
    Mol Pharmacol; 2021 Nov; 100(5):428-455. PubMed ID: 34452975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review regarding the article 'Targeting inflammatory signaling pathways with SGLT2 inhibitors: Insights into cardiovascular health and cardiac cell improvement'.
    He X; Yuan D
    Curr Probl Cardiol; 2024 Jun; 49(6):102563. PubMed ID: 38599557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke.
    Al Hamed FA; Elewa H
    Clin Ther; 2020 Nov; 42(11):e242-e249. PubMed ID: 33008610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors.
    Prandi FR; Barone L; Lecis D; Belli M; Sergi D; Milite M; Lerakis S; Romeo F; Barillà F
    Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
    Basile JN
    J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.
    Fattah H; Vallon V
    Drugs; 2018 May; 78(7):717-726. PubMed ID: 29663292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.
    Tanaka A; Shimabukuro M; Okada Y; Sugimoto K; Kurozumi A; Torimoto K; Hirai H; Node K;
    Cardiovasc Diabetol; 2020 Jun; 19(1):85. PubMed ID: 32534578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes and vascular disease: basic concepts of nitric oxide physiology, endothelial dysfunction, oxidative stress and therapeutic possibilities.
    Capellini VK; Celotto AC; Baldo CF; Olivon VC; Viaro F; Rodrigues AJ; Evora PR
    Curr Vasc Pharmacol; 2010 Jul; 8(4):526-44. PubMed ID: 19485895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes.
    Yaribeygi H; Atkin SL; Sahebkar A
    Diabetes Metab Syndr; 2019; 13(2):1679-1683. PubMed ID: 31336541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.